ASHP therapeutic position statement on the use of statins in the prevention of atherosclerotic vascular disease in adults.
Elevated blood cholesterol levels contribute significantly to ASVD and are often undertreated or not treated at all. Evaluation and management of lipid disorders should be guided by current NCEP guidelines. For patients with elevated cholesterol levels after appropriate therapeutic lifestyle changes, statins are a safe and effective means of reducing cardiovascular events. Because of their proven safety and effectiveness, ASHP supports the use of statins as first-line therapy for the primary and secondary prevention of atherosclerotic events.
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006302:Health Services Research; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D012957:Societies, Pharmaceutical; D014481:United States
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors